Pharmacological study on the molecular mechanism of crocodile blood in the treatment of lung cancer
Fang Pengyu

University of Cambridge，02138；

Abstract: Lung cancer is the most prevalent malignant tumor in terms of both incidence and mortality globally. Current therapeutic approaches still struggle to overcome clinical challenges such as drug resistance, metastasis, and immune evasion. This study systematically elucidates the multidimensional molecular mechanisms of crocodile blood in treating human lung cancer from a pharmacological perspective. At the tumor cell level, crocodile blood inhibits lung cancer cell proliferation by regulating cell cycle arrest, activating mitochondrial apoptosis pathways, and interfering with the EGFR/MAPK signaling axis. At the invasion and metastasis level, it suppresses metastasis by reversing epithelial-mesenchymal transition, downregulating MMP2/MMP9 activity, and blocking VEGF/VEGFR2 angiogenic signaling. At the immune microenvironment level, it enhances anti-tumor immune responses by inducing M1 macrophage polarization, boosting NK/CTL cytotoxicity, and reversing Treg-mediated immune suppression. The study demonstrates that crocodile blood exerts anti-lung cancer effects through "multi-target integrated regulation," providing a pharmacological basis for its development as an adjuvant therapy for lung cancer.

Keywords: crocodile blood; lung cancer; molecular mechanism

References

[1] Efficacy of Xianlong Granules combined with chemotherapy and immune checkpoint inhibitors in the first-line treatment of advanced non-small cell lung cancer [ J ].Chinese Journal of Gerontology, 2026,46 ( 05 ) :

[2] Wang Jianpo, Li Yaqiong, Zhang Zhen et al. [ 2 ].Comparison of the effects of 3D-CBCT and 4D-CBCT on precise radiotherapy in volumetric modulated arc therapy for lung cancer [ J ].Heilongjiang Medical Science, 2026,49 ( 03 ) : 90-93.

[3] Huang Jiangnan, Shen Chun, Chen Ziyi et al., from the ' intestinal flora-ERS ' to explore the role of ' upper and lower damage treatment ' in the immunotherapy of non-small cell lung cancer [ J / OL ].Oncology, 1-7 [ 2026-03-10 ].

[4] Hu Jiajie, Shi Lei.Research progress on biomarkers and efficacy prediction of immunotherapy for advanced non-small cell lung cancer [ J / OL ].International Journal of Medical Radiology, 1-7 [ 2026-03-10 ].

[5] Cheng Yanan, Zhang Yanyu, Kan Jianing, et al.. The mechanism and clinical application of Xuefu Zhuyu Decoction in the treatment of lung cancer [ J / OL ].Chinese Medical Journal, 1-19 [ 2026-03-10 ].